Altimmune Expands AdCOVID™ Manufacturing Collaboration With Lonza · BioBuzz biobuzz.io - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biobuzz.io Daily Mail and Mail on Sunday newspapers.
Published: Mar 12, 2021
Lonza to Commission a Dedicated Suite for Clinical and Commercial Supply of Altimmune’s COVID-19 Vaccine Candidate at its Houston Facility
GAITHERSBURG, Md. and BASEL, Switzerland, March 12, 2021 (GLOBE NEWSWIRE)
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has expanded its previously-announced AdCOVID manufacturing collaboration with Lonza. Under the expanded agreement, Lonza will commission a dedicated manufacturing suite for clinical and commercial production of AdCOVID, Altimmune’s single-dose intranasal vaccine candidate for COVID-19, at its facility near Houston, Texas.
“Manufacturing capacity for COVID-19 vaccines has been severely constrained, and this limitation has presented considerable challenges for vaccine developers,” said Dr. Vyjayanthi Krishnan, Ph.D., Vice President of Product Development for Altimmune. “By expanding our Lonza collaboration and commissioning our own d
Altimmune Extends Lonza Partnership To Support Production Of AdCOVID yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
FILE PHOTO: Logo of Swiss contract drug maker Lonza is seen in Basel
ZURICH (Reuters) – Lonza will commission a dedicated suite at its Houston viral vectors factory for clinical and commercial supply of U.S.-based Altimmune’s COVID-19 vaccine candidate, the Swiss contract drug manufacturer said on Friday.
Altimmune is developing a COVID-19 vaccine candidate to be administered via nasal spray, and has begun Phase 1 safety studies in humans, with expected data to come in the second quarter.
Lonza’s 300,000-square-foot cell and gene therapy factory, opened in 2018, will provide manufacturing space for Altimmune’s AdCOVID vaccine, which uses an adenovirus vector to help stimulate an immune response. The deal follows Lonza’s larger agreement with Moderna to produce drug substances for its mRNA vaccine in the United States and Switzerland.
Altimmune Expands AdCOVID™ Manufacturing Collaboration with Lonza apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.